Author Archives: admin


The most searched songs on Google in 2021 – Market Research Telecast

Every year, Google reveal what they were Searches that were highlighted in the last 12 months, making certain items a trend. For example, the company can show which films were most investigated by viewers, as well as series or even the actors and celebrities who stood out for a film or even a scandal during the year. Therefore, here we tell you what they were the most searched songs in 2021.

The song MAP refers to the combination between the first syllables of the words mom and dad. This theme had a launch, through Sony Music, in May 2021 and was performed by the Filipino boy band SB19. Today they have 1,190,820 monthly listeners through Spotify and there are more and more followers of the group formed by Pablo, Stell, Josh, Ken and Justin.

Performed by country music singer Walker Hayes, the simple Fancy Like was one of the most searched on Google in 2021. This song was released in August of this year on the occasion of the EP Country Stuff via Monument Records Nashville. Months later, in September, the American published a remix that had the participation of Kesha and that further triggered the song.

The American rapper Lil Nas X He led all the 2021 rankings with his songs. For this reason, their presence was evident in the most wanted during the year. Your song Industry Baby, In collaboration with Jack Harlow, it was very successful. Its launch was in July through Columbia Records and featured the co-production of Kanye West, making the single proposal even more attractive.

Another of the undisputed hits of Lil Nas X this year it was MONTERO (Call Me By Your Name). Also through Columbia Records, was released in March 2021. This was the lead single from his first studio album Montero, which was finally released in full in September of this year. It was written by himself with Take a Daytrip, Omer Fedi and Roy Lorenzo.

If it is about female voices, Olivia rodrigo was the main one of 2021. The actress and singer who rose to fame with High School Musical: The Musical: The Series, dazzled with his album Sour. However, long before publication, she distinguished herself with her single drivers license, written by her with Dan Nigro. Although it debuted in January of this year, 12 months later it is still the most searched song on Google.

If you have a Telegram account, just click on the following button.

But if you dont have a profile on the platform yet, you can download it from the Apple Store or the Google Store, depending on your cell phones operating system. Once inside the application, in the search engine put SpoilerBV and there you can give us subscribe to be aware of all the news.

Disclaimer: This article is generated from the feed and not edited by our team.

Read the original here:
The most searched songs on Google in 2021 - Market Research Telecast

SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients…

PRAGUE, Czech Republic, Dec. 08, 2021 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., through its subsidiaries, to evaluate the combination of SOT101, SOTIO’s IL-15 superagonist, and MSD’s KEYTRUDA® (pembrolizumab) in patients with selected advanced/refractory solid tumors in the phase 2 AURELIO-04 study.

See more here:
SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients...

Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

HAMPTON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 1 study of CDX-0159 for the treatment of prurigo nodularis (PN). CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. PN is a chronic skin disease that causes hard, intensely itchy lumps/nodules to form on the skin. The itching (pruritus) can be intense, causing people to scratch themselves to the point of bleeding or pain, which can form lesions and perpetuate the disease cycle.

Read more here:
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis

Sugarmade Provides Corporate Update as Nug Avenue Sees Accelerating Growth Ahead of Further Expansion

NEW YORK, NY, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Sugarmade, Inc. (OTC Pink: SGMD) ("Sugarmade", "SGMD" or the "Company") an emerging leader in the vertically integrated California cannabis marketplace, is pleased to provide this update to its shareholders as the Company moves toward new growth initiatives while continuing to expand organically within the framework of its primary operating vision.

Continued here:
Sugarmade Provides Corporate Update as Nug Avenue Sees Accelerating Growth Ahead of Further Expansion

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s Disease (PD).

Visit link:
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line…

WALTHAM, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the initiation of the CONTERNO study, a global, randomized Phase 3 trial of cosibelimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with non-squamous non-small cell lung cancer (NSCLC). The primary endpoint for the CONTERNO Phase 3 trial is overall survival (OS), and the study is designed to support full regulatory approvals worldwide.

Continue reading here:
Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line...

Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting

REDWOOD CITY, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data on JSP191 showing long-term benefits of hematopoietic stem cells (HSC) engraftment following targeted single-agent JSP191 conditioning in the treatment of severe combined immunodeficiency (SCID) will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting.

The rest is here:
Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting

Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis

BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS), today announced phase 3 topline results from the wearABLe study evaluating the non-inferiority (NI) of abaloparatide transdermal system (abalo-TDS) compared to abaloparatide subcutaneous injection (TYMLOS) in postmenopausal women with osteoporosis.

Original post:
Radius Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis

New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

Basel, December 8, 2021 — Novartis today announced new Kisqali® (ribociclib) data demonstrating a consistent overall survival (OS) benefit with Kisqali plus endocrine therapy (ET) across genomic subtypes of hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer (mBC), similarly in the indolent as well as in the aggressive, endocrine therapy (ET)-resistant subtypes6. The findings will be presented as a late-breaking oral presentation at the 2021 San Antonio Breast Cancer Symposium (SABCS).

The rest is here:
New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer